Poll

POLL: Do you know how to recognize blastic plasmacytoid dendritic cell neoplasm (BPDCN)?

Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Articles

A 13-year-old boy presenting an asymptotic dark violaceous infiltrated nodular lesion located on the left cheek was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often presents with skin manifestations.

Diagnosis, management challenging for pediatric BPDCN

Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632. 

Target therapies under study to treat BPDCN

A recently published article details the clinical and biological features, and patient outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy. 

Data describes BPDCN’s clinical, biological features and patient outcomes 

B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.

Venetoclax monotherapy for cutaneous BPDCN

Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.

CD123-targeted therapies promising in BPDCN and AML

Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.

A recent paper details the different ways scientists are investigating tagraxofusp to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy that often presents with skin manifestations.

Tagraxofusp treatment for BPDCN continues to evolve

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.    

Tagraxofusp comparable to other chemo regimens as first-line therapy

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

What dermatologists should know about blastic plasmacytoid dendritic cell neoplasm 

Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.